Form 4: MAIA CEO Vitoc Boosts Stake with 2025 Share Purchases

Sentiment:

Insider Transaction Report (Form 4) 25 November 2025 4:15 PM

📋All filings for Maia Biotechnology, INC

MAIA Biotechnology's CEO, Vlad Vitoc, increased his direct ownership in the company by purchasing 11,800 shares of common stock in late November 2025.

Better than expectedThe CEO, Vlad Vitoc, increased his direct stake in the company by purchasing 11,800 shares of common stock, signaling confidence in the company's future.

Summary

Vlad Vitoc, Chief Executive Officer, Director, and 10% Owner of MAIA Biotechnology, Inc. (MAIA), reported transactions involving the company's common stock.
On November 21, 2025, Mr. Vitoc acquired 1,800 shares of common stock at a weighted average price of $0.92 per share. The purchase price for these shares ranged from $0.9128 to $0.9235.
On November 24, 2025, he acquired an additional 10,000 shares of common stock at a price of $0.9891 per share.
Following these transactions, Mr. Vitoc directly beneficially owns 820,921 shares of MAIA Biotechnology common stock.
Additionally, Mr. Vitoc indirectly beneficially owns 210,100 shares through his spouse, disclaiming beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The CEO's open market purchases of company stock indicate strong confidence in the company's valuation and future performance, which is generally a positive signal for investors.

Positives

CEO Vlad Vitoc increased his direct ownership in MAIA Biotechnology by 11,800 shares through open market purchases.
The insider buying demonstrates management's confidence in the company's future prospects and valuation.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders may view the CEO's increased stake as a positive signal of management's belief in the company's prospects, potentially boosting investor confidence.

Key Dates

Date	Description
11/21/2025	Transaction Date: Acquisition of 1,800 shares of Common Stock by Vlad Vitoc.
11/24/2025	Transaction Date: Acquisition of 10,000 shares of Common Stock by Vlad Vitoc.
11/25/2025	Signature Date of Reporting Person Vlad Vitoc for the Form 4 filing.

Recommendation

hold

The reported insider purchases by CEO Vlad Vitoc, totaling 11,800 shares, signal management's confidence in MAIA Biotechnology's future. While insider buying is generally a positive indicator, a 'hold' recommendation is prudent as this Form 4 filing alone does not provide sufficient information on the company's broader financial health, operational performance, or strategic outlook to warrant a stronger recommendation without further comprehensive analysis.

Keywords

MAIA Biotechnology, MAIA, Vlad Vitoc, Insider Trading, Form 4, Stock Purchase, CEO, Director, 10% Owner

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.